• Emrah Salman, Salih Çetiner, Barış Boral, Filiz Kibar, Eren Erken, Emine Duygu Ersözlü, Suade Özlem Badak, Reyhan Bilici Salman, Yaşar Sertdemir, Alev Çetin Duran, and Akgün Yaman.
• Department of Immunology, Ankara City Hospital, Ankara, Turkey
• Turk J Med Sci. 2019 Oct 24; 49 (5): 149815021498-1502.

Background/AimRheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation. The study aimed to assess serum 14-3-3eta, anti-CarP, and anti-Sa in seronegative RA (SNRA) patients who were treatment-naïve as well as in healthy subjects. This is the first study in the literature to examine these autoantibodies together in SNRA patients.Materials And MethodsForty-five treatment-naïve SNRA patients and 45 healthy subjects were recruited. Drugs change the levels of autoantibodies; therefore, patients who took any medication had been excluded from our study. Anti-carbamylated protein, anti-Sa, and 14-3-3eta were measured by using three different ELISA kits.ResultsMedian serum concentration of healthy controls in 14-3-3eta was 0.02 (0.02–0.27) ng/mL. Median serum concentration of SNRA patients in 14-3-3eta was 1.00 (0.48–1.28) ng/mL. Data were analyzed with Mann–Whitney U tests; the P-value was <0.001 in 14-3-3eta. Receiver operating characteristic (ROC) curve analysis showed that 14-3-3eta in SNR compared to healthy controls had a significant (P < 0.001) area under the curve (AUC) of 0.90 (95% confidence interval, 0.83–0.96). At a cutoff of ≥0.33 ng/mL, the ROC curve yielded a sensitivity of 88.9%, a specificity of 82.2%, a positive predictive value of 83.3%, and a negative predictive value of 88.1%.ConclusionWe found that 14-3-3eta can be used as a diagnostic marker in SNRA.This work is licensed under a Creative Commons Attribution 4.0 International License.

24 keywords...

hide…